(CercleFinance.com) – Sanofi and AstraZeneca announce that the United States CDC Advisory Committee unanimously recommends Beyfortus (nirsevimab-alip) for the routine immunization of infants against RSV (respiratory syncytial virus) infections.
This recommendation, which applies to all infants under eight months of age, follows the FDA’s earlier-than-expected approval of Beyfortus and the unanimous vote of the FDA Advisory Committee.
The committee also came out unanimously in favor of including Beyfortus in the childhood immunization program and in favor of equitable access for all eligible infants. It will be made available before the start of the 2023-24 viral season.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends with the buttons below.
